Glucagon-like peptide 1 receptor agonists, including semaglutide, have increased in use and will continue to increase due to their effectiveness in weight loss.

This study found that nearly 17 million adolescents and young adults were eligible for glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy. One in 5 young adults eligible for GLP-1RAs ...

A multicenter French study led by Rennes University Hospital reports potential benefits of glucagon-like peptide-1 receptor ...

Employers explore glucagon-like peptide-1 (GLP-1) therapies' impact on health benefits, showcasing accountability and ...

Serena Williams has long been subjected to ill-tasted criticism over her weight. Her recent collaboration with a healthy ...

Serena Williams has revealed that she's taking a GLP-1 injectable weight loss treatment, in addition to her health regimen.

Longer-term studies will be needed to track whether per-patient costs might drop over time with continued use of the meds.

This retrospective cohort study found that taking glucagon-like peptide-1 receptor agonists (GLP-1RAs) was associated with a reduced overall risk of cancer, including lower risks of endometrial, ...

GLP-1 receptor agonists show promise in treating hidradenitis suppurativa, offering significant symptom relief and improved ...

USA: A recent study published in Diabetes, Obesity and Metabolism has reported that the use of glucagon-like peptide-1 ...

Serena Williams revealed how she turned her health around with the help of a GLP-1 medication after she struggled to lose ...

After years of struggling with postpartum weight gain despite strict training and healthy eating, the 23-time Grand Slam ...